BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform

Needham & Company Cut PT, But Keeps 'Buy' on Ionis Pharmaceuticals (IONS) Amid Update

Needham & Company analyst Chad Messer is sticking with his Buy rating but reducing his target to $55 (from $88) on Ionis Pharmaceuticals (NASDAQ: IONS) after Ionis announced that partner GSK is delaying its decision to initiate that study until after NEURO-TTR reads out in 1H:17. Severe thrombocytopenia... More

Leerink Remains Cautious on Ionis Pharmaceuticals (IONS) Following Conference Call

Leerink Partners analyst Michael Schmidt weighed in on Ionis Pharmaceuticals (NASDAQ: IONS) after the company held a conference call this morning to discuss GSK's decision not to initiate the planned "CARDIO-TTR" Phase III trial of IONS-TTR-Rx in patients with TTR amyloid cardiomyopathy (FAC).

Schmidt notes this decision... More

Cowen Downgrades Ionis Pharmaceuticals (IONS) to Market Perform

Cowen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $35.26 yesterday.

Alnylam Pharma (ALNY) Gains on Ionis (IONS) Setback

Alnylam Pharma (NASDAQ: ALNY) is gaining sharply Thursday (11.9%), related to a setback for Ionis Pharmaceuticals's (Nasdaq: IONS) IONIS-TTRRx program. Ionis' partner GSK has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. IONS is down 32%.

Ionis Pharma (IONS): CARDIO-TTR Trial Uncertainty as GSK Stops Initiation - BMO

BMO Capital Markets analyst, Do Kim, notes that Ionis Pharmaceuticals (NASDAQ: IONS) partner GSK will not initiate the CARDIO-TTR Phase III trial, following the FDA clinical hold related to patient safety monitoring in the study design. He believes that the study is probably... More

Ionis Pharma (IONS) Says Glaxo Will Not Initiate CARDIO-TTR Phase 3

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) provided an update on the IONIS-TTRRx program. Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardiomyopathy.

GSK, which has an option to exclusively license IONIS-TTRRx, has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. As announced in April 2016, the U.S. Food and Drug... More